Table 2.

Summary of clinical outcomes for unmatched cohorts of hospitalized COVID-19 patients who have taken either Heparin or Enoxaparin. For categorical variables such as mortality status and complications, patient counts are shown with the percentage of each cohort in parentheses. For numeric variables such as hospital and ICU length of stay, the mean value for each cohort is shown with standard deviation in parentheses. In addition, Benjamini-Hochberg adjusted p-values are shown for the statistical tests comparing the outcome variables for the matched Enoxaparin and Heparin cohorts.

Outcome variable	Enoxaparin, but not Heparin (Original)	Heparin, but not Enoxaparin (Original)	p-value	BH-adjusted p-value	Risk ratio (95% CI)
Number of patients	441	166
Deceased (ever)	11 (2.5%)	28 (17%)	2.7e−9	1.3e−8	6.76 (3.39, 12.7)
Deceased 28 days within first day of hospitalization (out of patients with known mortality status)	9/244 (3.7%)	20/118 (17%)	3.8e−5	4.7e−5	4.60 (2.13, 9.29)
ICU admission	88 (20%)	50 (30%)	9.1e−3	0.01	1.51 (1.12, 2.03)
Hospital length of stay in days	5.4 (4.3)	7.4 (6.6)	0.02	0.02
ICU length of stay in days	0.92 (2.5)	2.3 (5.4)	4.5e−3	7.5e−3